secwatch / observer
8-K filed March 2, 2026, 6:59 PM ET ticker RNTX CIK 0001420565
debt confidence high sentiment negative materiality 0.70

Rein Therapeutics issues $2.875M in unsecured notes to institutional investors at 20% OID

Rein Therapeutics, Inc.

item 1.01item 2.03item 3.02item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001193125-26-084012
form_type
8-K
ticker
RNTX
cik
0001420565
company_name
Rein Therapeutics, Inc.
filed_at
2026-03-02T23:59:59+00:00
discovered_at
2026-05-14T18:02:35.043013+00:00
generated_at
2026-05-15T22:34:55.982813+00:00
sec_items
["1.01", "2.03", "3.02", "9.01"]
event_type
debt
sentiment
negative
materiality_score
0.7
calibrated_materiality_score
0.7
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001193125-26-084012
json_url
https://secwatch.observer/filing/0001193125-26-084012.json
markdown_url
https://secwatch.observer/filing/0001193125-26-084012.md
text_url
https://secwatch.observer/filing/0001193125-26-084012.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1420565/000119312526084012/0001193125-26-084012-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1420565/000119312526084012/d121919d8k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

122dd453942f7d521d74bbd9ad15b9e204bbd690

Rein Therapeutics, Inc. incurred senior notes of $2,875,000 with three institutional investors at 20% original issue discount maturing the earlier of (i) the date of the closing of the next issuance and sale of securities of the Company, in a single transaction or series of related transactions.

On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).

SEC 8-K Item 2.03/2.04 confidence 0.9 SEC evidence

1d9bcbb6366c1040c55605929a4c4f8512de5c10

Rein Therapeutics, Inc. entered into Purchase Agreement with three institutional investors valued at $2,875,000.

On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

Comparable filings

BTU

Peabody prices $250M convertible notes due 2031, repurchases $241.2M of 2028 notes

PEABODY ENERGY CORP June 2, 2026, 10:17 AM ET debt Items 1.01, 2.03, 3.02, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).

Comparable filing

additional $25 million in aggregate principal amount of the Notes (together with the “Initial Notes,” the “Notes”), bringing the total aggregate principal amount of the Notes to $250 million. On June 2, 2026, the Company completed the private offering of the Notes. The Notes are senior unsecured obligations of the Company. The net proceeds from this offering were

Filing page SEC filing

CBLO

C2 Blockchain raises $130K and up to $1.2M via convertible notes with heavy dilution

C2 Blockchain, Inc. June 2, 2026, 10:08 AM ET debt Items 1.01, 2.03, 3.02, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).

Comparable filing

On May 22, 2026, the Company entered into a Securities Purchase Agreement with Auctus Fund, LLC (“Auctus”), pursuant to which the Company issued and sold a Promissory Note in the principal amount of $130,000 (the “Auctus Note”).

Filing page SEC filing

EMAT

EMAT secures $100M convertible debenture facility from Yorkville; first $20M tranche issued

Evolution Metals & Technologies Corp. May 11, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 7.01, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).

Comparable filing

The first Convertible Debenture (the “First Debenture”) in the principal amount of $20,000,000 was issued on May 7, 2026.

Filing page SEC filing

TBH

Brag House issues $2.5M convertible notes at 25% OID; proceeds for House of Doge merger

Brag House Holdings, Inc. May 8, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).

Comparable filing

The issuance of the Notes in the aggregate original principal amount of $2,500,000 constitutes the creation of a direct financial obligation of the Company. The Notes bear interest at 12.0% per annum, mature on February 4, 2027

Filing page SEC filing

KNX

Knight-Swift closes $1.5B convertible note offering at 1.00% due 2031; proceeds used to repay term loans and revolver

Knight-Swift Transportation Holdings Inc. May 8, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 8.01, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).

Comparable filing

On May 8, 2026, Knight-Swift Transportation Holdings Inc. (the "Company") completed its previously announced private offering (the "Offering") of $1.5 billion aggregate principal amount of 1.00% Convertible Senior Notes due 2031

Filing page SEC filing

TCPC

BlackRock TCP Capital closes $535.8M CLO securitization, repays existing debt facilities

BlackRock TCP Capital Corp. June 1, 2026, 4:50 PM ET debt Items 1.01, 1.02, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).

Comparable filing

Item 1.01. Entry into a Material Definitive Agreement. On May 27, 2026 (the " Closing Date "), BlackRock TCP Capital Corp. (the " Company "), through its subsidiary, completed a $535,780,000 securitization of certain loans held by a subsidiary of the Company (the " CLO Transaction "). On the Closing Date and in connection with the CLO Transaction, BlackRock DLF 2026-C

Filing page SEC filing

VVX

V2X refinances $868.5M term loans with new tranche maturing 2030; SOFR+2% margin

V2X, Inc. June 1, 2026, 4:10 PM ET debt Items 1.01, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).

Comparable filing

The Amendment provides for, among other things, a new tranche of term loans under the Credit Agreement in an aggregate original principal amount of $868,522,978.38 (the “New Term Loans”), which New Term Loans replace or refinance in full all of the existing term loans outstanding under the Credit Agreement (as in effect immediately prior to the Amendment), as further set forth in the Amendment. The New Term Loans mature on December 6, 2030.

Filing page SEC filing

SST

System1 exchanges $302.6M debt for $150M term loan, $39.3M preferred stock, and cash

System1, Inc. June 1, 2026, 9:00 AM ET debt Items 1.01, 2.03, 3.02, 7.01, 9.01

same fact type: debt_financing same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On February 24 and 27, 2026, Rein Therapeutics, Inc. (the “Company”) entered into separate securities purchase agreements (each a “Purchase Agreement”) with three institutional investors pursuant to which the Company issued and sold to the investors, in a private placement, unsecured promissory notes in the aggregate original principal amount of $2,875,000 (each a “Note”).

Comparable filing

specified in the Exchange Agreement on the terms and subject to the conditions set forth therein. The consideration under the Exchange Agreement consists of (i) a new $150.0 million term loan facility held by the Participating Lenders (the “Priority Term Loans”), (ii) the issuance of 39,250 shares of Series A Cumulative Convertible Preferred Stock (the

Filing page SEC filing

Source: SEC EDGAR
accession 0001193125-26-084012
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.